Zobrazeno 1 - 10
of 209
pro vyhledávání: '"Minoru Tsuda"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 3, Pp n/a-n/a (2023)
Abstract Dersimelagon (formerly MT‐7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X‐linked protoporphy
Externí odkaz:
https://doaj.org/article/8c0fa5619e474aa9b0fcfcd6b9ae3e38
Autor:
Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Hikida, Minoru Tsuda-Tsukimoto, Akira Saito, Kenji Arakawa, Kiichiro Ueta, Masabumi Minami, Masaharu Shiotani
Publikováno v:
Journal of Pharmacological Sciences, Vol 132, Iss 4, Pp 255-261 (2016)
We investigated whether structurally different sodium–glucose cotransporter (SGLT) 2 inhibitors, when co-administered with dipeptidyl peptidase-4 (DPP4) inhibitors, could enhance glucagon-like peptide-1 (GLP-1) secretion during oral glucose toleran
Externí odkaz:
https://doaj.org/article/78a15480dadc48cda92be98d11ee68cc
Autor:
Kittipong Tachampa, Michio Takeda, Suparat Khamdang, Rie Noshiro-Kofuji, Minoru Tsuda, Surawat Jariyawat, Toshiyuki Fukutomi, Samaisukh Sophasan, Naohiko Anzai, Hitoshi Endou
Publikováno v:
Journal of Pharmacological Sciences, Vol 106, Iss 3, Pp 435-443 (2008)
Mycotoxins are secondary metabolites of moulds that which exert adverse effects in humans and animals. It is known that direct cellular toxicity is often associated with increased cellular accumulation of toxic compounds, and membrane transport may b
Externí odkaz:
https://doaj.org/article/f387b77a36874d128ddfa77c93faa380
Autor:
Kei Ogawa, Ryosuke Ide, Kirstine Belongie, Minoru Tsuda, Hiroki Kawanishi, Renli Teng, Akihito Ogasawara
Publikováno v:
Clinical Pharmacology in Drug Development. 12:493-501
Publikováno v:
Pharmacology Research & Perspectives. 11
Autor:
Akihito Ogasawara, Kei Ogawa, Ryosuke Ide, Yuka Ikenaga, Chie Fukunaga, Satoshi Nakayama, Minoru Tsuda
Publikováno v:
European Journal of Clinical Pharmacology.
Purpose To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Methods In this
Publikováno v:
Marine Engineering. 57:362-368
Autor:
Minoru Tsuda, Kazuyuki Maeda
Publikováno v:
Marine Engineering. 56:585-591
Autor:
Tadashi Makino, Kazuyuki Maeda, Minoru Tsuda, Munekatsu Furugen, Hidetsugu Sasaki, Tatsuro Tsukamoto
Publikováno v:
Marine Engineering. 56:265-272
Autor:
Minoru Tsuda, Kazuyuki Maeda
Publikováno v:
Marine Engineering. 52:514-519